QDEL - キデル （Quidel Corporation）

Quidel press release (QDEL): Q1 Non-GAAP EPS of $1.80 beats by $0.37.Revenue of $846.1M (-15.4% Y/Y) beats by $73.94M.Growth in non-respiratory revenue for the first quarter was…

QuidelOrtho presents with attractive business economics. Read more about QDEL here.

NEWARK, DE / ACCESSWIRE / March 29, 2023 / The global Swab And Viral Transport Medium Market could reach about US$ 8.86 billion in 2023, according to FMI''s recent market analysis. By 2033, FMI also anticipated that the market could expand at a 5.8% CAGR and reach a value of US$ 15.60 billion. During the COVID-19 pandemic, there has been a rise in demand for swabs and viral transport mediums. Companies have improved their manufacturing capacity to manufacture items suitable for viral collection, maintenance, and culture as a result of research institutions and labs stepping up their efforts to develop COVID-19 vaccines. Companies in the swab and viral transport medium business are producing inventive kits with vials, double-ended flocked swabs, medications, and other items that avoid bacterial or fungal contamination. They are concentrating on a better solution formulation to stop the growth of bacterial and fungal flora. The market is expanding owing to new viral transport medium solutions.

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in Orlando, Florida, on March 7, 2023. Douglas Bryant, president and chief executive off

QuidelOrtho presents with attractive business economics. Read more about QDEL here.

NEWARK, DE / ACCESSWIRE / March 29, 2023 / The global Swab And Viral Transport Medium Market could reach about US$ 8.86 billion in 2023, according to FMI''s recent market analysis. By 2033, FMI also anticipated that the market could expand at a 5.8% CAGR and reach a value of US$ 15.60 billion. During the COVID-19 pandemic, there has been a rise in demand for swabs and viral transport mediums. Companies have improved their manufacturing capacity to manufacture items suitable for viral collection, maintenance, and culture as a result of research institutions and labs stepping up their efforts to develop COVID-19 vaccines. Companies in the swab and viral transport medium business are producing inventive kits with vials, double-ended flocked swabs, medications, and other items that avoid bacterial or fungal contamination. They are concentrating on a better solution formulation to stop the growth of bacterial and fungal flora. The market is expanding owing to new viral transport medium solutions.

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in Orlando, Florida, on March 7, 2023. Douglas Bryant, president and chief executive off

https://www.investing.com/news/pro/quidel-corp-pt-raised-to-99-at-ubs-432SI-3010508

NEWARK, DE / ACCESSWIRE / March 29, 2023 / The global Swab And Viral Transport Medium Market could reach about US$ 8.86 billion in 2023, according to FMI''s recent market analysis. By 2033, FMI also anticipated that the market could expand at a 5.8% CAGR and reach a value of US$ 15.60 billion. During the COVID-19 pandemic, there has been a rise in demand for swabs and viral transport mediums. Companies have improved their manufacturing capacity to manufacture items suitable for viral collection, maintenance, and culture as a result of research institutions and labs stepping up their efforts to develop COVID-19 vaccines. Companies in the swab and viral transport medium business are producing inventive kits with vials, double-ended flocked swabs, medications, and other items that avoid bacterial or fungal contamination. They are concentrating on a better solution formulation to stop the growth of bacterial and fungal flora. The market is expanding owing to new viral transport medium solutions.

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in Orlando, Florida, on March 7, 2023. Douglas Bryant, president and chief executive off

https://www.investing.com/news/pro/quidel-corp-pt-raised-to-99-at-ubs-432SI-3010508

Major players in the influenza diagnostics market are F. Hoffmann-La Roche Ltd, Quidel Corporation, ?h?rm? F??h?r, Abbott Laboratories, Hologic, Becton Dickinson and Company, DiaSorin S.p.A., Luminex Corporation, Meridian Bioscience Inc. Major players in the influenza diagnostics market are F. Hoffmann-La Roche Ltd, Quidel Corporation, ?h?rm? F??h?r, Abbott Laboratories, Hologic, Becton Dickinson and Company, DiaSorin S.p.A., Luminex Corporation, Meridian Bioscience Inc.